Nucleix (Israel)
Bladder EpiCheck® Bladder EpiCheck®, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer.
Basic Information
- Category: Business
- Website: http://nucleix.com/
Documented Facts
- Email: http://www.menarinidiagnostics.com/ (No linked source recorded for this statement.)
Evidence and Sources
- Nucleix (Israel) — Official Website (official)
Citation Guidance
Explore Business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Nucleix (Israel).
- Canonical profile: https://brandsource.ai/brands/nucleix-israel
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/nucleix-israel/json-ld
- Citation profile API: https://brandsource.ai/api/brands/nucleix-israel/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-23
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Bladder EpiCheck® Bladder EpiCheck®, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.